Clinical Trial Update: A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624 [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study of DR10624 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics, conducted by Zhejiang Doer Biologics Co., Ltd.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• DR10624

Snippet

Sponsor: Zhejiang Doer Biologics Co., Ltd. | Conditions: Healthy, Obesity, Metabolically | Phase 1 | Status: COMPLETED